Achieves Goal in Successful Crowdfunding Campaign

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign
Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine

Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform.

Read the full article at businesswire.com

0